103 related articles for article (PubMed ID: 35394507)
1. The impact of pausing the Oxford-AstraZeneca COVID-19 vaccine on uptake in Europe: a difference-in-differences analysis.
Jain V; Lorgelly P
Eur J Public Health; 2022 Aug; 32(4):648-654. PubMed ID: 35394507
[TBL] [Abstract][Full Text] [Related]
2. Sustained COVID-19 vaccine willingness after safety concerns over the Oxford-AstraZeneca vaccine.
Sønderskov KM; Dinesen PT; Østergaard SD
Dan Med J; 2021 Mar; 68(5):. PubMed ID: 33870886
[TBL] [Abstract][Full Text] [Related]
3. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
[TBL] [Abstract][Full Text] [Related]
4. Isolated thrombosis after COVID-19 vaccination: case series.
Al-Ahmad M; Al Rasheed M; Altourah L; Rodriguez-Bouza T; Shalaby N
Int J Hematol; 2022 Feb; 115(2):153-157. PubMed ID: 34993889
[TBL] [Abstract][Full Text] [Related]
5. Self-reported side effects of the Oxford AstraZeneca COVID-19 vaccine among healthcare workers in Ethiopia, Africa: A cross-sectional study.
Yesuf EA; Riad A; Sofi-Mahmudi A; Sudhakar M; Mekonnen A; Endalkachew S; Mama F; Muhidin S; Ayele B; Yahya M; Usman A; Abafita J; Klugar M
Front Public Health; 2022; 10():937794. PubMed ID: 35928493
[TBL] [Abstract][Full Text] [Related]
6. Increment of D-dimer Associated with Immune Thrombotic Thrombocytopenia in ChAdOx1 nCoV-19 Vaccinated Individuals.
Ornelas-Aguirre JM; Gómez-Alcalá AV; Ramírez-Leyva DH
Arch Med Res; 2022 Jun; 53(4):341-351. PubMed ID: 35534335
[TBL] [Abstract][Full Text] [Related]
7. Vocal fold paralysis following first dose of Oxford-AstraZeneca coronavirus disease 2019 vaccine.
Jama GM; Amin M; Hassaan A; Kaddour H
J Laryngol Otol; 2022 May; 136(5):466-468. PubMed ID: 35510490
[TBL] [Abstract][Full Text] [Related]
8. Middle-age Asian male with cerebral venous thrombosis after COVID-19 AstraZeneca vaccination.
Guan CY; Tsai SH; Fan JS; Lin YK; Kao CC
Am J Emerg Med; 2022 Jan; 51():427.e3-427.e4. PubMed ID: 34274191
[TBL] [Abstract][Full Text] [Related]
9. The Effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca Vaccines to Prevent Severe COVID-19 in Costa Rica: Nationwide, Ecological Study of Hospitalization Prevalence.
Rosero-Bixby L
JMIR Public Health Surveill; 2022 May; 8(5):e35054. PubMed ID: 35483079
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
[TBL] [Abstract][Full Text] [Related]
11. Infographics on risks associated with COVID-19 and the willingness to get the AstraZeneca vaccine: two randomized online experiments.
Felgendreff L; Siegers R; Otten L; Betsch C
BMC Public Health; 2024 Feb; 24(1):529. PubMed ID: 38378506
[TBL] [Abstract][Full Text] [Related]
12. Acute onset ocular myasthenia gravis after vaccination with the Oxford-AstraZeneca COVID-19 vaccine.
Maher DI; Hogarty D; Ben Artsi E
Orbit; 2023 Dec; 42(6):630-634. PubMed ID: 35499172
[TBL] [Abstract][Full Text] [Related]
13. Coincidental Onset of Ocular Myasthenia Gravis Following ChAdOx1 n-CoV-19 Vaccine against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Galassi G; Rispoli V; Iori E; Ariatti A; Marchioni A
Isr Med Assoc J; 2022 Jan; 24(1):9-10. PubMed ID: 35077038
[TBL] [Abstract][Full Text] [Related]
14. A Case of
Chhabra N; George A
Curr Drug Saf; 2023 Apr; 18(4):584-588. PubMed ID: 35702789
[TBL] [Abstract][Full Text] [Related]
15. Oxford-AstraZeneca COVID-19 vaccine: need of a reasoned and effective vaccine campaign.
Vallée A; Chan-Hew-Wai A; Bonan B; Lesprit P; Parquin F; Catherinot É; Choucair J; Billard D; Amiel-Taieb C; Camps È; Cerf C; Zucman D; Fourn E
Public Health; 2021 Jul; 196():135-137. PubMed ID: 34198072
[TBL] [Abstract][Full Text] [Related]
16. The winding 12-month journey of the AstraZeneca COVID-19 vaccine since its first administration to humans.
Dal-Ré R
Therapie; 2023; 78(3):293-302. PubMed ID: 35907680
[TBL] [Abstract][Full Text] [Related]
17. Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia (VITT).
Varona JF; García-Isidro M; Moeinvaziri M; Ramos-López M; Fernández-Domínguez M
Eur J Intern Med; 2021 Sep; 91():90-92. PubMed ID: 34256983
[No Abstract] [Full Text] [Related]
18. Side-Effects following Oxford/AstraZeneca COVID-19 Vaccine in Tororo District, Eastern Uganda: A Cross-Sectional Study.
Onyango J; Mukunya D; Napyo A; Nantale R; Makoko BT; Matovu JKB; Wanume B; Okia D; Okello F; Okware S; Olupot-Olupot P; Lubaale Y
Int J Environ Res Public Health; 2022 Nov; 19(22):. PubMed ID: 36430019
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the serum levels of CCL2, CCL3, and IL-29 after first and second administrations of the COVID-19 vaccine (Oxford-AstraZeneca).
Bagheri-Hosseinabadi Z; Kaeidi A; Rezvani M; Taghipour Khaje Sharifi G; Abbasifard M
Immunobiology; 2024 Mar; 229(2):152789. PubMed ID: 38290406
[TBL] [Abstract][Full Text] [Related]
20. Adverse effects following COVID-19 vaccination in Iran.
Babaee E; Amirkafi A; Tehrani-Banihashemi A; SoleimanvandiAzar N; Eshrati B; Rampisheh Z; Asadi-Aliabadi M; Nojomi M
BMC Infect Dis; 2022 May; 22(1):476. PubMed ID: 35585518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
